摘要
系统性治疗是晚期肝细胞癌病人首选的治疗方式。阿替利珠单克隆抗体联合贝伐珠单克隆抗体可以为晚期肝细胞癌病人带来更好的生存获益。笔者报道1例术后复发肝细胞癌病人行阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗的疗效和安全性管理,其研究结果显示:用药期间肿瘤存在“假性进展”可能,持续部分缓解≥2年,效果良好。
Systemic treatment is the first choice for patients with advanced hepatocellular carcinoma.Atezolizumab combined with bevacizumab can bring better survival for patients with advanced hepatocellular carcinoma.The authors introduce the efficacy and safety management of a hepatocellular carcinoma case with postoperative recurrence who received treatment of atezolizumab combined with bevacizumab.The patient had a probability of pseudoprogression during treatment,and had a good result of a continuous partial response over 2 years.
作者
袁佳
陆申新
曹屹岭
李苗
干育红
张岚
Yuan Jia;Lu Shenxin;Cao Yiling;Li Miao;Gan Yuhong;Zhang Lan(Department of Hepatic Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2021年第S02期1-4,共4页
Chinese Journal of Digestive Surgery
关键词
肝肿瘤
免疫治疗
靶向治疗
联合治疗
假性进展
Liver neoplasms
Immunotherapy
Targeted therapy
Combination therapy
Pseudoprogression
作者简介
通信作者:张岚,Email:zhang.lan@zs-hospital.sh.cn
